The legal complaint alleges that ADMA executives concealed critical information from the market during the 19-month period. Specifically, the suit claims the company relied on undisclosed related-party transactions and utilized channel stuffing to artificially inflate reported revenue figures. These actions, combined with allegedly inadequate internal controls, rendered the company’s public statements about its business operations materially misleading.
ADMA Biologics Faces Securities Fraud Class Action Over Revenue Claims
Investors who incurred significant losses in ADMA Biologics between August 2024 and March 2026 have until August 10, 2026, to apply as lead plaintiffs in a pending securities fraud lawsuit. The Law Offices of Howard G. Smith represents the class, alleging the company misled shareholders regarding its financial health.
Shareholders who held ADMA stock during this window are not required to take immediate action to remain part of the class, though those seeking to lead the litigation must contact the Law Offices of Howard G. Smith by the August 10 deadline. The firm is currently coordinating with affected investors to discuss legal rights and potential recovery of losses.
Comments (0)
No comments yet. Be the first!